Clinical effectiveness of probiotics therapy in persistent ulcerative colitis symptom after endoscopic remission

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0002879

Enrollment

Registered

2018-05-18

Start date

2018-04-27

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : All of enrolled patients will take a drug which name is Biotop capsule(Lactobacillus Acidophilus 75 mg , Clostridium Butyricum Toa 25 mg, Bacillus Mesentericus Toa 25 mg, Streptococcus Faecalis

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with IBS-like symptom that meet the ROME-IV diagnostic criteria among patients with ulcerative colitis with a Mayo clinic endoscopy subscore 0-1 point (endoscopic remission)

Exclusion criteria

Exclusion criteria: Patients who are younger than 19 years of age, have a Mayo clinic endoscopy subscore score of 2 or more, patients who have had proctitis or proctosigmoiditis by other causes such as infection, medication, radiation, ischemia, or Crohn's disease within 3 months of enrollment, patients using steroids, patients with a genetic problem such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption

Design outcomes

Primary

Measure	Time frame
Stool frequency;stool form;abdominal pain frequency	—

Secondary

Measure	Time frame
Change in quality of life	—

Countries

Korea, Republic of

Contacts

Public ContactKYUNGJOONG KIM

Inje University Haeundae Paik Hospital

jabezkj@gmail.com+82-51-797-0200

Outcome results